Synapse - Works

Results (5608)

Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)

Meeting Abstract

Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Phase I/II trial of oral masofaniten (EPI-7386) in combination with enzalutamide (Enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects

Meeting Abstract

Kyriakopoulos, C.; Chatta, G.; Laccetti, A. L.; Iannotti, N.; Sokolova, A. O.; Hotte, S. J.; Tutrone, R.; Markowski, M. C.; Nordquist, L. T.; Pili, R.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore

Meeting Abstract

Chi, K. N.; Sartor, O.; Fizazi, K.; de Bono, J. S.; Shore, N. D.; Herrmann, K.; Castellano Gauna, D. E.; Piulats Rodriguez, J. M.; Flechon, A.; Wei, X. X.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig

Meeting Abstract

Armstrong, A. J.; Appleman, L. J.; Danila, D. C.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P. J.; Pook, D. W.; Kim, M.; Dorff, T. B.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Abida, W.; Appleman, L. J.; Taplin, M. E.; Juárez, Á.; Zhang, L.; Chen, Y.; Gupta, N.; Saltzstein, D.
Annals of Oncology (2024)

Fulltext@MSK | Save

Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial

Meeting Abstract

Hofman, M. S.; Gafita, A.; Bressel, M.; Alipour, R.; Levy, S.; Emmett, L.; Ravi Kumar, A. S.; Hamid, A. A.; Buteau, J. P.; Kuo, P. H.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

Meeting Abstract

Fizazi, K.; Morris, M. J.; Shore, N. D.; Chi, K. N.; Crosby, M.; de Bono, J. S.; Herrmann, K.; Roubaud, G.; Nagarajah, J.; Fleming, M. T.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study

Meeting Abstract

Kelly, W. K.; Appleman, L. J.; Lin, C. C.; Armstrong, A. J.; Fischer, S. C.; Pook, D. W.; Perez Gracia, J. L.; Lee, J. L.; Berthold, D. R.; Ward, P. J.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castrationresistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D.; Patel, M. R.; Choudhury, A. D.; Rasco, D.; Lakhani, N. J.; Hawley, J.; Srinivas, S.; Aparicio, A.; Narayan, V.; Runcie, K.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors

Meeting Abstract

Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save